Modus Therapeutics Holding AB is a Swedish public limited company and governed by Swedish legislation, mainly the Swedish Companies Act (2005: 551) and the Swedish Annual Accounts Act (1995: 1554). Following the listing of the Company’s shares on First North, the Company also applies First North’s rules.
In addition to Swedish legislation and First North’s regulations, it is the Company’s Articles of Association and its internal corporate governance guidelines that underpin the Company’s corporate governance. The articles of association state, among other things, the seat of the Board, the focus of the business, the limits of the share capital and the number of shares and the conditions for attendance at the Annual General Meeting.
According to the Company's Articles of Association, the Board of Directors shall consist of a minimum of three and a maximum of seven Board members with no deputy directors. The Company's Board of Directors currently consists of three board members without deputy directors. The Board members are elected for the period until the end of the Annual General Meeting of 2021.
At the Annual General Meeting 2021 Ernst & Young AB, with the principal accountant Oskar Wall, was appointed the company's auditor until the end of the Annual General Meeting to be held next financial year.